News | January 04, 2022
Domestic and emerging markets will drive pharma growth: ICRA
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
The company has developed the API in house at its R&D center in Hyderabad
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
